Helping Alaska Native people quit smoking using a personalized approach

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention focuses on using the Nicotine Metabolite Ratio (NMR) to tailor pharmacologic treatments for smoking cessation among Alaska Native and American Indian individuals. It is a single-arm pilot trial aimed at assessing the acceptability and feasibility of this personalized approach. Participants will undergo blood tests and provide saliva samples to inform their treatment plans, and they must be willing to attempt quitting smoking within 30 days of enrollment. The study is conducted in collaboration with Southcentral Foundation and aims to improve smoking abstinence rates in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

(Patients)

* Alaska Native or American Indian person by self-report
* eligible for or already receiving services at Southcentral Foundation (SCF)
* age 18 years or older
* daily smoking in the past 30-days
* if other nicotine or tobacco products are used, cigarettes are main product used
* planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days
* willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program
* willing to have a blood test to inform their treatment
* willing to try a pharmacologic treatment
* willing to provide a saliva sample
* has phone service
* has access to broadband internet on mobile phone at home, work, or other location
* has an Android or iPhone mobile phone compatible with the Smokerlyzer app

(Staff)

\- Staff participants of qualitative interviews to assess acceptability and feasibility of the intervention must be a health care professional at Southcentral Foundation (SCF), involved in the care of one of the participants of the study, that is their care team staff; including but not limited to: primary care providers, tobacco treatment specialists/health educators, pharmacists, nurse case managers, behavioral health consultants, certified medical assistants, and lab technicians.

Exclusion Criteria:

(Patients)

* Participated in the prior study phase
* participated in a cessation program during the past 3 months
* their provider has not approved varenicline in their referral to the Quit Tobacco Program
* has history of serious hypersensitivity or skin reactions to varenicline
* has bleeding disorder or is currently receiving cancer treatment
* questionable capacity or impaired decision-making capacity

Where it's running

• Anchorage Native Primary Care Center
  Anchorage, Alaska, United States Recruiting

Study contacts

• Principal investigator: Georgia J Michlig, PhD — Southcentral Foundation
• Study coordinator: Georgia Michlig, PhD
• Email: gmichlig@SouthcentralFoundation.com
• Phone: 907-729-5421

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quitting Matters: a smoking quit program for people living with HIV

  This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06883097

• Smoky Futures: Danish Adolescent Nicotine Use over Time

  This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.

  Recruiting University of Southern Denmark · Copenhagen · NCT07910331

• Nicotine Orodispersible Tablet to Relieve Cravings in Smokers

  A nicotine mint orodispersible tablet is tested vs placebo to see if it quickly eases the urge to smoke in adult cigarette smokers.

  Recruiting Phase 2 Kenvue Brands LLC · Mississauga, Ontario · NCT07893158

• Optimizing when weekly chatbot reminders go out to people using a chatbot for quitting smoking

  This study tests whether sending weekly reminders at different times helps people stay engaged with a chatbot smoking-cessation service.

  Recruiting The University of Hong Kong · Hong Kong · NCT07826884

• NMDA and Sigma-1 combination therapy for smoking cessation with AXS-05

  This phase 3 trial tests whether AXS-05 can help adults quit smoking better than placebo or bupropion.

  Recruiting at 28 sites Phase 3 Axsome Therapeutics, Inc. · Phoenix, Arizona and 27 other locations · NCT07766655

• AI-assisted interactive case-based training to improve smoking cessation counseling by medical interns

  This study tests whether AI-powered interactive case-based training helps medical interns provide better smoking cessation counseling.

  Recruiting Assiut University · Asyut, Assuit · NCT07650721

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.